Seres Therapeutics (NASDAQ:MCRB) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report issued on Friday.

Several other equities analysts also recently commented on the stock. The Goldman Sachs Group cut their price target on shares of Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating on the stock in a report on Friday, March 14th. Chardan Capital reissued a “neutral” rating and issued a $6.00 price objective (up from $1.25) on shares of Seres Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, Seres Therapeutics has an average rating of “Hold” and an average price target of $73.67.

Seres Therapeutics Trading Up 1.4%

Shares of NASDAQ:MCRB opened at $7.05 on Friday. The company has a market capitalization of $61.46 million, a price-to-earnings ratio of -30.65 and a beta of 2.89. Seres Therapeutics has a 12 month low of $6.64 and a 12 month high of $30.60. The firm’s 50-day moving average is $11.67 and its 200 day moving average is $14.66.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.67) by ($1.57). As a group, equities analysts forecast that Seres Therapeutics will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently added to or reduced their stakes in MCRB. Geode Capital Management LLC boosted its position in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares during the period. Virtu Financial LLC lifted its position in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares during the period. Vontobel Holding Ltd. lifted its position in shares of Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 543,469 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock worth $720,000 after purchasing an additional 117,107 shares during the period. Finally, Avantax Advisory Services Inc. lifted its position in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the period. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.